Sanofi ADR (SNY)vsTaseko Mines Ltd (TGB)
SNY
Sanofi ADR
$43.31
+0.30%
HEALTHCARE · Cap: $103.45B
TGB
Taseko Mines Ltd
$7.49
+3.31%
BASIC MATERIALS · Cap: $2.65B
Smart Verdict
WallStSmart Research — data-driven comparison
Sanofi ADR generates 6937% more annual revenue ($47.35B vs $672.90M). SNY leads profitability with a 16.0% profit margin vs -4.5%. TGB appears more attractively valued with a PEG of 0.33. SNY earns a higher WallStSmart Score of 51/100 (C-).
SNY
Buy51
out of 100
Grade: C-
TGB
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+25.0%
Fair Value
$62.70
Current Price
$43.31
$19.39 discount
Margin of Safety
-17.4%
Fair Value
$7.11
Current Price
$7.49
$0.38 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Strong operational efficiency at 20.0%
Generating 1.7B in free cash flow
Growing faster than its price suggests
Revenue surging 45.3% year-over-year
Areas to Watch
ROE of 6.6% — below average capital efficiency
Expensive relative to growth rate
Earnings declined 11.7%
Elevated debt levels
Weak financial health signals
ROE of -4.7% — below average capital efficiency
Earnings declined 45.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : SNY
The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.
Bull Case : TGB
The strongest argument for TGB centers on PEG Ratio, Revenue Growth. Revenue growth of 45.3% demonstrates continued momentum. PEG of 0.33 suggests the stock is reasonably priced for its growth.
Bear Case : SNY
The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.
Bear Case : TGB
The primary concerns for TGB are Debt/Equity, Piotroski F-Score, Return on Equity. Debt-to-equity of 1.58 is elevated, increasing financial risk.
Key Dynamics to Monitor
SNY profiles as a mature stock while TGB is a hypergrowth play — different risk/reward profiles.
TGB carries more volatility with a beta of 2.02 — expect wider price swings.
TGB is growing revenue faster at 45.3% — sustainability is the question.
SNY generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
SNY scores higher overall (51/100 vs 48/100), backed by strong 16.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Sanofi ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
Taseko Mines Ltd
BASIC MATERIALS · COPPER · USA
Taseko Mines Limited, a mining company, acquires, develops and operates mineral properties. The company is headquartered in Vancouver, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?